Story perspectives

Moderna CEO Halts Trials; Shares Rise Amid Uncertainty

1/24/2026

Summary

Story summary

Stéphane Bancel, Moderna's chief executive officer, announced Moderna would not fund late-stage vaccine trials.
Moderna's shares rose 4.2% to $51.87 after the announcement.
The move follows increasing resistance from U.S. officials and a shift in the vaccine market described as less reliable.
Investors see Moderna's personalized cancer vaccine with Merck as growth, but policy uncertainties under Health Secretary Robert F. Kennedy Jr. threaten the outlook ahead of February 13 results.

1 of 1

Story summary

Stéphane Bancel, Moderna's chief executive officer, announced Moderna would not fund late-stage vaccine trials.
Moderna's shares rose 4.2% to $51.87 after the announcement.
The move follows increasing resistance from U.S. officials and a shift in the vaccine market described as less reliable.
Investors see Moderna's personalized cancer vaccine with Merck as growth, but policy uncertainties under Health Secretary Robert F. Kennedy Jr. threaten the outlook ahead of February 13 results.